News Breaks |
|
|
| October 25, 2012 |
| 06:03 EDT |  | SNY, NVS, AZN, RHHBY | Drug companies face increased competition as more patents expire, WSJ reports
As three major Europe drug makers saw their earnings decline in Q3, it underscored the challenge facing pharmaceutical companies as drugs lose patent protection and competition increases from cheaper versions, reports the Wall Street Journal. Drug companies in general are facing the worst effects of the "patent cliff" this quarter, where patents for drugs expire in major territories but aren't replaced quickly enough to replace lost revenues. Reference Link |
|
|
News For AZN;RHHBY;NVS;SNY From The Last 14 Days Check below for free stories on AZN;RHHBY;NVS;SNY the last two weeks. |
|
|
| May 24, 2013 |
| 16:07 EDT |  | AZN | Actavis confirms appeal court issues injunction related to Resupules
Actavis (ACT) confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort Respules 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the court. |
|
| 08:22 EDT |  | NVS, AZN | Leerink's biotech analysts hold an analyst/industry conference call
 Subscribe for More Information |
|
| May 23, 2013 |
| 15:19 EDT |  | RHHBY | FDA announces approval of Roche diabetes test
Subscribe for More Information |
|
| 08:18 EDT | | SNY | Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi
Subscribe for More Information |
|
| May 22, 2013 |
| 10:33 EDT | | RHHBY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:00 EDT |  | RHHBY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| 06:02 EDT | | RHHBY | Roche upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT | | RHHBY | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
| |
| 07:44 EDT | | NVS, SNY | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 17:26 EDT | | SNY, RHHBY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT | | RHHBY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 11:27 EDT | | SNY | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
|
| 08:03 EDT | | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
Subscribe for More Information |
| |
|
|
|
|
